BAM
LUCD icon

Belpointe Asset Management’s Lucid Diagnostics LUCD Stock Holding History

Belpointe Asset Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,500
Closed -$2.1K – 2165
2023
Q1 		$2.1K Hold
1,500
– – ﹤0.01% 3295
2022
Q4 		$2.04K Buy
+1,500
New +$2.7K ﹤0.01% 3254

Other funds holding LUCD

LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Belpointe Asset Management's LUCD Position: Q2 2023 in Review

Belpointe Asset Management sold out of Lucid Diagnostics (LUCD) in Q2 2023, closing a stake of 1,500 shares — an estimated $2.1K sold.

Belpointe Asset Management first reported a position in LUCD in Q4 2022 and held it in 2 quarters. The position peaked at $2.1K in Q1 2023. 18 funds tracked by Wall St. Rank hold LUCD as of Q2 2023.

  • Belpointe Asset Management reported no remaining Lucid Diagnostics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,500 Lucid Diagnostics shares in Q2 2023, an estimated $2.1K.
  • Belpointe Asset Management first reported a position in Lucid Diagnostics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Lucid Diagnostics position peaked at $2.1K in Q1 2023.
  • 18 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.